Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.42 |
| ▸ | CTPS2 | Q9NRF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088712 | 1.00 | CYP11B2 (0.49) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL30620697 | 0.88 | CYP11B2 (0.45) | CYP11B2CYP11B1CTPS1CTPS2 | |
| SCHEMBL30455283 | 0.85 | RXRB (0.53) | CYP11B2PIM1CSNK2A1CYP11B1CTPS1 | |
| SCHEMBL24088666 | 0.85 | RXRB (0.53) | CYP11B2PIM1CSNK2A1CYP11B1CTPS1 | |
| SCHEMBL24088755 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1CTPS1CTPS2 | |
| SCHEMBL31676635 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1CTPS1CTPS2 | |
| SCHEMBL25607375 | 0.81 | CYP11B2 (0.57) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL24088759 | 0.80 | CYP11B2 (0.49) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL30455860 | 0.80 | CYP11B2 (0.49) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL21391994 | 0.79 | CHEK1 (0.56) | CYP11B2PIM3CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-116601131-A | CTPS1 inhibitor and application thereof | 林伯士克洛索有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CYP11B2 10/4885PIM1 1455/4885CSNK2A1 1511/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CYP11B2 10/4885PIM1 1455/4885CSNK2A1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.